©2024 Stanford Medicine
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Not Recruiting
Trial ID: NCT00375830
Purpose
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F)
fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance
imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or
stage II-IV prostate cancer.
Official Title
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Robert Herfkens
Professor of Radiology (Cardiovascular Imaging), Emeritus
Shreyas Vasanawala, MD/PhD
William R. Brody Professor of Pediatric Radiology and Child Health
Eligibility
All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).
INCLUSION CRITERIA
- ≥ 18 years old at the time of the drug administration
- ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
(PSA) > 10 micrograms/L OR recurrent breast or prostate cancer
- Capable of complying with study procedures
- Able to remain still for duration of imaging procedure (about one hour)
- Written informed consent
EXCLUSION CRITERIA
- Pregnant or nursing
- Metallic implants that contraindicate MRI
- Renal function impairment that contraindicates MRI
Intervention(s):
drug: Gadopentetate dimeglumine
drug: Gadofosveset
drug: Gadobutrol
procedure: Bone scan
procedure: Positron Emission Tomography (PET) scan
drug: 18F-Fludeoxyglucose (18F-FDG)
procedure: Computed Tomography (CT) scan
drug: 18F-Sodium Fluoride (18F-NaF)
procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
drug: 99mTc-methyl diphosphonate
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061